BSX Boston Scientific Corporation
Healthcare$57.64-0.24%ClosedMarket Cap: $85.67B
As of 2026-05-26
Valuation
P/E (TTM)
31.78
PEG
0.57
P/B
3.32
P/S
4.17
EV/EBITDA
20.03
DCF Value
$81.36
FCF Yield
4.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
70.4%
Operating Margin
20.1%
Net Margin
17.2%
ROE
14.8%
ROA
8.0%
ROIC
9.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $5.20B | 69.4% | $1.07B | $1.34B | $— | — |
| Q4 null | $5.29B | 74.5% | $1.21B | $668.0M | $— | — |
| FY null | $20.07B | 69.0% | $3.97B | $2.89B | $— | — |
| Q3 null | $5.07B | 69.9% | $1.05B | $755.0M | $— | — |
| Q2 null | $5.06B | 67.7% | $819.0M | $793.0M | $— | — |
| Q1 null | $4.66B | 63.3% | $896.0M | $674.0M | $— | — |
| Q4 null | $4.56B | 58.6% | $589.0M | $566.0M | $— | — |
| FY null | $16.75B | 61.3% | $2.63B | $1.85B | $— | — |
| Q3 null | $4.21B | 62.9% | $674.0M | $469.0M | $— | — |
| Q2 null | $4.12B | 62.7% | $747.0M | $324.0M | $— | — |
| Q1 null | $3.86B | 61.8% | $644.0M | $494.0M | $— | — |
| Q4 2023 | $3.73B | 62.1% | $558.0M | $504.0M | $0.34 | — |